Payment overview · 2025
General Payments
$234.97
11 reported records · 4 companies
Healthcare provider profile · identity verified
Daniel L Hayward, MD
Allopathic & Osteopathic Physicians|Internal Medicine · BRIDGMAN, MI · NPI 1285679365
Verified facts
What the public records show
CMS Open Payments records show Daniel L Hayward, MD received $234.97 in general payments during 2025 across 11 reported records.
Novo Nordisk Inc accounted for 44.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Trelegy Ellipta.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 49 claims for Myrbetriq by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 161 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 42 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 104 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $104.47 | 44.5% | 5 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $89.09 | 37.9% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $22.03 | 9.4% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $19.38 | 8.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $234.97 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $63.99 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $44.26 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $40.48 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $40.48 | 2 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $23.03 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $22.03 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $21.80 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $19.38 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 161 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 104 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 42 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
49 | 15 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
161 | 47 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
42 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
104 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1129 | 346 |
| Amlodipine Besylate | Amlodipine Besylate | 750 | 232 |
| Losartan Potassium | Losartan Potassium | 522 | 162 |
| Lisinopril | Lisinopril | 443 | 142 |
| Levothyroxine Sodium | Levothyroxine Sodium | 441 | 125 |
| Irbesartan | Irbesartan | 408 | 129 |
| Metformin Hcl | Metformin Hcl | 330 | 110 |
| Metoprolol Tartrate | Metoprolol Tartrate | 300 | 81 |
| Metoprolol Succinate | Metoprolol Succinate | 293 | 100 |
| Tamsulosin Hcl | Tamsulosin Hcl | 293 | 77 |
| Simvastatin | Simvastatin | 288 | 85 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 281 | 93 |
| Chlorthalidone | Chlorthalidone | 268 | 86 |
| Omeprazole | Omeprazole | 264 | 91 |
| Hydrochlorothiazide | Hydrochlorothiazide | 209 | 68 |
| Gabapentin | Gabapentin | 202 | 51 |
| Allopurinol | Allopurinol | 182 | 50 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 180 | 36 |
| Pantoprazole Sodium | Pantoprazole Sodium | 166 | 50 |
| Eliquis | Apixaban | 161 | 47 |
| Alprazolam | Alprazolam | 160 | 43 |
| Sertraline Hcl | Sertraline Hcl | 160 | 56 |
| Furosemide | Furosemide | 152 | 54 |
| Escitalopram Oxalate | Escitalopram Oxalate | 146 | 36 |
| Potassium Chloride | Potassium Chloride | 146 | 43 |
| Trazodone Hcl | Trazodone Hcl | 126 | 43 |
| Trulicity | Dulaglutide | 123 | 27 |
| Carvedilol | Carvedilol | 122 | 36 |
| Torsemide | Torsemide | 117 | 43 |
| Finasteride | Finasteride | 112 | 31 |
| Metformin Hcl Er | Metformin Hcl | 105 | 41 |
| Ozempic | Semaglutide | 104 | 22 |
| Atenolol | Atenolol | 103 | 30 |
| Tramadol Hcl | Tramadol Hcl | 100 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 31 |
| Quetiapine Fumarate | Quetiapine Fumarate | 97 | 15 |
| Meloxicam | Meloxicam | 95 | 36 |
| Jardiance | Empagliflozin | 73 | 27 |
| Famotidine | Famotidine | 65 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 64 | 23 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 64 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 63 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 62 | 22 |
| Ezetimibe | Ezetimibe | 61 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 58 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 19 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | 17 |
| Synthroid | Levothyroxine Sodium | 52 | 16 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 51 | 16 |
| Alendronate Sodium | Alendronate Sodium | 50 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 49 | 16 |
| Donepezil Hcl | Donepezil Hcl | 49 | 19 |
| Myrbetriq | Mirabegron | 49 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 47 | 13 |
| Spironolactone | Spironolactone | 46 | 15 |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 45 | 15 |
| Bupropion Xl | Bupropion Hcl | 45 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 44 | 14 |
| Warfarin Sodium | Warfarin Sodium | 44 | 15 |
| Mirtazapine | Mirtazapine | 43 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 41 | 14 |
| Lansoprazole | Lansoprazole | 40 | 12 |
| Lorazepam | Lorazepam | 40 | 11 |
| Benazepril Hcl | Benazepril Hcl | 39 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 39 | 12 |
| Xarelto | Rivaroxaban | 39 | 14 |
| Oxycodone Hcl | Oxycodone Hcl | 38 | suppressed |
| Celecoxib | Celecoxib | 37 | 11 |
| Enalapril Maleate | Enalapril Maleate | 37 | 11 |
| Lovastatin | Lovastatin | 37 | suppressed |
| Cephalexin | Cephalexin | 35 | 28 |
| Glimepiride | Glimepiride | 35 | 13 |
| Montelukast Sodium | Montelukast Sodium | 35 | 13 |
| Ramipril | Ramipril | 35 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 32 | 11 |
| Pregabalin | Pregabalin | 32 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 31 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 31 | 13 |
| Valacyclovir | Valacyclovir Hcl | 30 | 17 |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Dutasteride | Dutasteride | 26 | suppressed |
| Acyclovir | Acyclovir | 25 | suppressed |
| Olanzapine | Olanzapine | 25 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 24 | suppressed |
| Diazepam | Diazepam | 24 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 24 | suppressed |
| Nystatin | Nystatin | 24 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 23 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 21 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 17 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Entresto | Sacubitril/Valsartan | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 17 | suppressed |
| Premarin | Estrogens, Conjugated | 17 | suppressed |
| Glipizide Er | Glipizide | 16 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Valsartan | Valsartan | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 15 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 14 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Nabumetone | Nabumetone | 13 | suppressed |
| Prednisone | Prednisone | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 12 | suppressed |
| Lumigan | Bimatoprost | 12 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 12 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 11 | suppressed |
| Mounjaro | Tirzepatide | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Rhopressa | Netarsudil Mesylate | 11 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $234.97 · 11 records | Novo Nordisk Inc | BEXSERO, ELIQUIS, Ozempic, Rybelsus, SHINGRIX, TRELEGY ELLIPTA, Veozah, Wegovy | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error